Aytu BioPharma (NASDAQ:AYTU) Releases Earnings Results, Misses Estimates By $0.37 EPS

Aytu BioPharma (NASDAQ:AYTU) issued its quarterly earnings results on Thursday. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.37), Zacks reports. Aytu BioPharma had a negative return on equity of 31.31% and a negative net margin of 14.60%. The business had revenue of $17.98 million for the quarter.

Aytu BioPharma Stock Performance

Shares of NASDAQ:AYTU opened at $2.36 on Friday. Aytu BioPharma has a one year low of $1.87 and a one year high of $3.50. The stock has a market capitalization of $14.09 million, a price-to-earnings ratio of -0.90 and a beta of -1.43. The company has a 50-day simple moving average of $2.53 and a 200-day simple moving average of $2.83.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.